Dabigatran-induced gastrointestinal bleeding in an elderly patient with moderate renal impairment

Annals of Pharmacotherapy

Volumn 46, Issue 4, 2012, Pages

  Wychowski, Maura K ^a   Kouides, Peter A ^b  

^a ROCHESTER GENERAL HOSPITAL   (United States)

^b UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

Author keywords

Dabigatran; Elderly; Renal function

Indexed keywords

BLOOD CLOTTING FACTOR 9 COMPLEX; CREATININE; DABIGATRAN; FLUTICASONE; GLIPIZIDE; HEMOGLOBIN; HYDROCHLOROTHIAZIDE; INSULIN GLARGINE; METFORMIN; METOPROLOL; POTASSIUM CHLORIDE; PRAVASTATIN; SALMETEROL; VITAMIN K GROUP; WARFARIN;

ACUTE KIDNEY FAILURE; AGED; ANTICOAGULATION; ARTICLE; ASTHMA; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; CONGESTIVE HEART FAILURE; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DIALYSIS CATHETER; DISEASE DURATION; DISEASE SEVERITY; EPISTAXIS; ERYTHROCYTE CONCENTRATE; FEMALE; HEART ATRIUM FIBRILLATION; HEMATOCRIT; HEMODIALYSIS; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; INTERNATIONAL NORMALIZED RATIO; KIDNEY FUNCTION; LENGTH OF STAY; MENTAL HEALTH; NON INSULIN DEPENDENT DIABETES MELLITUS; NURSING HOME; OBESITY; PARTIAL THROMBOPLASTIN TIME; PERIPHERAL VASCULAR DISEASE; PRIORITY JOURNAL; RECURRENT DISEASE; THROMBIN TIME; THROMBOCYTE COUNT; TREATMENT DURATION; UPPER GASTROINTESTINAL BLEEDING; VOMITING;

ACUTE KIDNEY INJURY; AGED; ANTICOAGULANTS; ATRIAL FIBRILLATION; BENZIMIDAZOLES; BETA-ALANINE; CREATININE; FEMALE; GASTROINTESTINAL HEMORRHAGE; HUMANS; INTERNATIONAL NORMALIZED RATIO; PATIENT SELECTION; RENAL DIALYSIS;

EID: 84859703006     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1Q747     Document Type: Article

References (12)

1. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361:1139-51.
2. Baetz BE, Spinler SA. Dabigatran etexilate: an oral direct thrombin inhibitor for prophylaxis and treatment of thromboembolic diseases. Pharmacotherapy 2008;28:1354-73.
3. van Ryn J, Stangier J, Haertter S, et al. Dabigatran etexilate-a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 2010;103: 1116-27.
4. Stangier J, Rathgen K, Stähle H, Mazur D. Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study. Clin Pharmacokinet 2010;49:259-68.
5. Product information. Pradaxa (dabigatran). Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, November 2011.
6. Beasley BN, Unger EF, Temple R. Anticoagulant options-why the FDA approved a higher but not a lower dose of dabigatran. N Engl J Med 2011;364:1788-90.
7. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1982;30:239-45.
8. Eerenberg ES, Kamphuisen PW, Sijpkens MK, et al. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation 2011;124:1573-9.
9. Stangier J, Rathgen K, Stähle H, et al. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol 2007;64:292-303.
10. Legrand M, Mateo J, Aribaud A, et al. The use of dabigatran in elderly patients. Arch Intern Med 2011;171:1285-8.
11. Coresh J, Astor B. Decreased kidney function in the elderly: clinical and preclinical, neither benign. Ann Intern Med 2006;145:299-301.
12. Pengo V, Crippa L, Falanga A, et al. Questions and answers on the use of dabigatran and perspectives on the use of other new oral anticoagulants in patients with atrial fibrillation. A consensus document of the Italian Federation of Thrombosis Centers (FCSA). Thromb Haemost 2011;106: 868-76.